Plasma and synovial fluid concentration of doxycycline following low-dose, low-frequency administration, and resultant inhibition of matrix metalloproteinase-13 from interleukin-stimulated equine synoviocytes.
Authors: Maher M C, Schnabel L V, Cross J A, Papich M G, Divers T J, Fortier L A
Journal: Equine veterinary journal
Summary
# Editorial Summary Osteoarthritis in horses involves progressive cartilage degradation driven partly by matrix metalloproteinase-13 (MMP-13), an enzyme that breaks down joint cartilage matrix. Researchers investigated whether sub-antimicrobial dosing of doxycycline—a tetracycline antibiotic with known MMP-inhibitory properties—could accumulate in synovial fluid at therapeutic concentrations without promoting antibiotic resistance, by administering low-dose doxycycline to horses and measuring plasma and synovial fluid drug levels alongside MMP-13 inhibition in cultured equine joint cells stimulated with inflammatory cytokines. Doxycycline achieved measurable concentrations in synovial fluid that significantly suppressed MMP-13 production from interleukin-stimulated synoviocytes, whilst remaining substantially below the minimum inhibitory concentration (MIC90) for common equine bacterial pathogens, demonstrating that chondroprotective effects can be separated from antimicrobial effects. These findings support the potential use of low-dose doxycycline as an adjunctive disease-modifying treatment in osteoarthritis management, offering a practical strategy to slow cartilage degradation without contributing to antibiotic resistance—a consideration of particular relevance given current antimicrobial stewardship concerns in veterinary practice.
Read the full abstract on PubMed
Practical Takeaways
- •Low-dose doxycycline can be used therapeutically for osteoarthritis management in horses without the concern of promoting bacterial resistance at typical equine pathogenic doses
- •This approach offers a practical, affordable option for managing joint inflammation and cartilage degradation in equine practice
- •The dual benefit of MMP-13 inhibition suggests doxycycline may slow degenerative processes while maintaining normal bacterial flora
Key Findings
- •Low-dose, low-frequency doxycycline administration achieves chondroprotective concentrations in synovial fluid while remaining below MIC90 of most equine pathogens
- •Doxycycline inhibits matrix metalloproteinase-13 (MMP-13) expression in interleukin-stimulated equine synoviocytes
- •This dosing strategy provides anti-inflammatory cartilage protection without promoting antimicrobial resistance